Bristol-Myers Squibb Plans To Make India Its Global Pharma Innovation Hub
This article was originally published in PharmAsia News
Executive Summary
HYDERABAD, India - Bristol-Myers Squibb may not be as aggressive as its larger multinational competitors in playing the generics or the branded generics card, but the company best known for blockbusters like Abilify (aripiprazole) and Plavix (clopidogrel) has brought under sharp focus partnership-based research for developing innovative drugs in India
You may also be interested in...
BMS, Biocon Team Up To Rekindle Oral Insulin Hopes
After faltering last year with clinical development of its oral insulin, Biocon’s long hunt for a partner ends with Bristol-Myers Squibb, which signed a carefully worded “exclusive option agreement.”
BMS, Biocon Team Up To Rekindle Oral Insulin Hopes
After faltering last year with clinical development of its oral insulin, Biocon’s long hunt for a partner ends with Bristol-Myers Squibb, which signed a carefully worded “exclusive option agreement.”
Biocon Chairman Kiran Mazumdar-Shaw On Hopes For An Oral Diabetes Drug, And Risks And Rewards Of Innovation: An Interview with PharmAsia News
Biocon Chairman And Managing Director Kiran Mazumdar-Shaw shares her business development strategy and newest pipeline developments with PharmAsia News in an exclusive interview.